New Cross-Regimen Analysis of HEALEY ALS Platform Trial Shows Significant Survival AdvantageSALT LAKE CITY, March 12, 2025 (GLOBE NEWSWIRE) -- Clene, Inc. (Nasdaq: CLNN) and its subsidiary, Clene ...

CNM-Au8 prolonged survival for people with ALS relative to those who received the investigational treatment zilucoplan or a ...

Tetramethylpyrazine nitrone was safe for people with amyotrophic lateral sclerosis (ALS), but neither a high nor low daily dose of the drug outperformed placebo for the primary outcome in a phase II ...

更糟糕的是，病情会持续恶化，大约在症状出现后的 3 - 5 年内，患者往往会因呼吸衰竭而失去生命。目前，ALS 还无法治愈，像 Riluzole 和 Edaravone 等药物，也只能在一定程度上延长患者的生命或减缓疾病的进展速度。 头痛，是一种极为常见的病症，全球超过半数 ...

Nevertheless, the new disappointment with DNL343 is another major disappointment to ALS patients, who have limited drug ...

Things changed in July last year, when Andrew noticed muscles twitching in his limbs; the spasms spread to his whole body ...

Thanks to advances in screening and research, more people are surviving lung cancer today than ever before. In the past 5 years, the survival rate for all people in U.S. rose by 26%. Unfortunately ...

78% of participants across both groups received standard ALS background therapy (riluzole, edaravone, or both) at baseline. These results are consistent with previous survival benefits observed in ...

Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science ...